Literature DB >> 12739885

Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice.

Nina Raben1, Kanneboyina Nagaraju, Alicia Lee, Nina Lu, Yesenia Rivera, Tejas Jatkar, John J Hopwood, Paul H Plotz.   

Abstract

When knockout mice are used to test the efficacy of recombinant human proteins, the animals often develop antibodies to the enzyme, precluding long-term pre-clinical studies. This has been a problem with a number of models, for example, the evaluation of gene or enzyme replacement therapies in a knockout model of glycogen storage disease type II (GSDII; Pompe syndrome). In this disease, the lack of acid alpha-glucosidase (GAA) results in lysosomal accumulation of glycogen, particularly in skeletal and cardiac muscle. Here, we report that in a GAA-deficient mouse model of GSDII, low levels of transgene-encoded human GAA expressed in skeletal muscle or liver dramatically blunt or abolish the immune response to human recombinant protein. Of two low expression transgenic lines, only the liver-expressing line exhibited a profound GAA deficiency in skeletal muscle and heart indistinguishable from that in the original knockouts. The study suggests that the induction of tolerance in animal models of protein deficiencies could be achieved by restricting the expression of a gene of interest to a particular, carefully chosen tissue.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12739885     DOI: 10.1023/a:1022998010833

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  34 in total

1.  Determination of acid alpha-glucosidase protein: evaluation as a screening marker for Pompe disease and other lysosomal storage disorders.

Authors:  K Umapathysivam; A M Whittle; E Ranieri; C Bindloss; E M Ravenscroft; O P van Diggelen; J J Hopwood; P J Meikle
Journal:  Clin Chem       Date:  2000-09       Impact factor: 8.327

2.  Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme.

Authors:  Nina Raben; Tejas Jatkar; Alicia Lee; Nina Lu; Sunita Dwivedi; Kanneboyina Nagaraju; Paul H Plotz
Journal:  Mol Ther       Date:  2002-11       Impact factor: 11.454

3.  Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.

Authors:  J M Van den Hout; A J Reuser; J B de Klerk; W F Arts; J A Smeitink; A T Van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

4.  Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase.

Authors:  A Amalfitano; A J McVie-Wylie; H Hu; T L Dawson; N Raben; P Plotz; Y T Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

5.  Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.

Authors:  D F Pauly; T J Fraites; C Toma; H S Bayes; M L Huie; R Hirschhorn; P H Plotz; N Raben; P D Kessler; B J Byrne
Journal:  Hum Gene Ther       Date:  2001-03-20       Impact factor: 5.695

6.  Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.

Authors:  Thomas J Fraites; Mary R Schleissing; R Andrew Shanely; Glenn A Walter; Denise A Cloutier; Irene Zolotukhin; Daniel F Pauly; Nina Raben; Paul H Plotz; Scott K Powers; Paul D Kessler; Barry J Byrne
Journal:  Mol Ther       Date:  2002-05       Impact factor: 11.454

7.  Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease.

Authors:  A G Bijvoet; E H van de Kamp; M A Kroos; J H Ding; B Z Yang; P Visser; C E Bakker; M P Verbeet; B A Oostra; A J Reuser; A T van der Ploeg
Journal:  Hum Mol Genet       Date:  1998-01       Impact factor: 6.150

Review 8.  Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models.

Authors:  D A Brooks
Journal:  Mol Genet Metab       Date:  1999-10       Impact factor: 4.797

9.  Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.

Authors:  T VandenDriessche; V Vanslembrouck; I Goovaerts; H Zwinnen; M L Vanderhaeghen; D Collen; M K Chuah
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

10.  Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.

Authors:  E D Kakkis; M F McEntee; A Schmidtchen; E F Neufeld; D A Ward; R E Gompf; S Kania; C Bedolla; S L Chien; R M Shull
Journal:  Biochem Mol Med       Date:  1996-08
View more
  10 in total

1.  Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.

Authors:  Patricia I Dickson; N Matthew Ellinwood; Jillian R Brown; Robert G Witt; Steven Q Le; Merry B Passage; Moin U Vera; Brett E Crawford
Journal:  Mol Genet Metab       Date:  2012-02-08       Impact factor: 4.797

2.  Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease.

Authors:  Tokiko Fukuda; Meghan Ahearn; Ashley Roberts; Robert J Mattaliano; Kristien Zaal; Evelyn Ralston; Paul H Plotz; Nina Raben
Journal:  Mol Ther       Date:  2006-09-27       Impact factor: 11.454

3.  Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.

Authors:  Priya S Kishnani; Paula C Goldenberg; Stephanie L DeArmey; James Heller; Danny Benjamin; Sarah Young; Deeksha Bali; Sue Ann Smith; Jennifer S Li; Hanna Mandel; Dwight Koeberl; Amy Rosenberg; Y-T Chen
Journal:  Mol Genet Metab       Date:  2010-01       Impact factor: 4.797

4.  Induction of tolerance to human arylsulfatase A in a mouse model of metachromatic leukodystrophy.

Authors:  Ulrich Matzner; Frank Matthes; Eva Herbst; Renate Lüllmann-Rauch; Zsuzsanna Callaerts-Vegh; Rudi D'Hooge; Cecilia Weigelt; Carl Eistrup; Jens Fogh; Volkmar Gieselmann
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

Review 5.  Therapeutic approaches in glycogen storage disease type II/Pompe Disease.

Authors:  Benedikt Schoser; Victoria Hill; Nina Raben
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

6.  The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.

Authors:  Suhrad G Banugaria; Sean N Prater; Yiu-Ki Ng; Joyce A Kobori; Richard S Finkel; Roger L Ladda; Yuan-Tsong Chen; Amy S Rosenberg; Priya S Kishnani
Journal:  Genet Med       Date:  2011-08       Impact factor: 8.822

7.  The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.

Authors:  Richie Khanna; John J Flanagan; Jessie Feng; Rebecca Soska; Michelle Frascella; Lee J Pellegrino; Yi Lun; Darlene Guillen; David J Lockhart; Kenneth J Valenzano
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

Review 8.  Gene Therapy Developments for Pompe Disease.

Authors:  Zeenath Unnisa; John K Yoon; Jeffrey W Schindler; Chris Mason; Niek P van Til
Journal:  Biomedicines       Date:  2022-01-28

9.  Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy.

Authors:  Juna M de Vries; Esther Kuperus; Marianne Hoogeveen-Westerveld; Marian A Kroos; Stephan C A Wens; Merel Stok; Nadine A M E van der Beek; Michelle E Kruijshaar; Dimitris Rizopoulos; Pieter A van Doorn; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  Genet Med       Date:  2016-06-30       Impact factor: 8.822

10.  Chronic enzyme replacement therapy ameliorates neuropathology in alpha-mannosidosis mice.

Authors:  Markus Damme; Stijn Stroobants; Meike Lüdemann; Michelle Rothaug; Renate Lüllmann-Rauch; Hans Christian Beck; Annika Ericsson; Claes Andersson; Jens Fogh; Rudi D'Hooge; Paul Saftig; Judith Blanz
Journal:  Ann Clin Transl Neurol       Date:  2015-09-19       Impact factor: 4.511

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.